Affinergy (Research Park, North Carolina) said that it has appointed two VPs to its leadership team. Carmella Moody has been VP of regulatory and quality assurance, and Bud Nelson has been promoted to VP intellectual property. Moody previously had positions in regulatory affairs, quality, and clinical trials with Constella Group, NextGen Pharma, Glaxo Wellcome, Covance Biotechnology Services, and Cato Research. Nelson has over 13 years experience as an intellectual property attorney in the biotech and pharmaceutical industries, and seven years experience as corporate legal counsel. Affinergy makes biological systems using linkers that adhere to proteins, drugs, cells, and biomaterial surfaces "in order to kick-start biology."

Ronald Sosnowski, PhD, has been named VP of R&D for Adnavance Technologies (San Diego). Sosnowski was most recently senior director of molecular biology and research for Nanogen. Adnavance is a diagnostic company developoing DNA-based tests using its metalized-DNA platform.